Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: The Ambulatory Medical Assistance (AMA) experience

International Journal of Nursing Studies

Volumn 48, Issue 8, 2011, Pages 926-932

  Compaci, Gisèle ^a   Ysebaert, Loic ^a   Obéric, Lucie ^a   Derumeaux, Hélène ^b   Laurent, Guy ^a  

^a CHU PURPAN   (France)

^b Hôtel Dieu   (France)

Author keywords

Chemotherapy; Health care quality; Medication compliance; Oncologic nursing

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; TELEPHONE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; TELEPHONE;

EID: 79960627410     PISSN: 00207489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijnurstu.2011.01.008     Document Type: Article

References (27)

1. Black K.L. Standardization of telephone triage in pediatric oncology. Journal of Pediatric Oncology Nursing 2007, 24(4):190-199.
2. Bosly A., Bron D., Van Hoof A., De Bock R., Berneman Z., Ferrant A., Kaufman L., Dauwe M., Verhoef G. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Annals of Hematology 2008, 87(4):277-283.
3. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., Lister T.A., Vose J., Grillo-López A., Hagenbeek A., Cabanillas F., Klippensten D., Hiddemann W., Castellino R., Harris N.L., Armitage J.O., Carter W., Hoppe R., Canellos G.P. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. Journal of Clinical Oncology 1999, 17(4):1244-1253. NCI Sponsored International Working Group.
4. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine 2002, 346(4):235-242.
5. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Fermé C., Christian B., Lepage E., Tilly H., Morschhauser F., Gaulard P., Salles G., Bosly A., Gisselbrecht C., Reyes F., Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology 2005, 23(18):4117-4126.
6. Habermann T.M., Weller E.A., Morrison V.A., Gascoyne R.D., Cassileth P.A., Cohn J.B., Dakhil S.R., Woda B., Fisher R.I., Peterson B.A., Horning S.J. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology 2006, 24(19):3121-3127.
7. Hirakawa T., Yamaguchi H., Yokose N., Gomi S., Inokuchi K., Dan K. Importance of maintaining the relative dose intensity of CHO-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Annals of Hematology 2010, 89(9):897-904.
8. Formica V., Fossile E., Pellegrino R., Fatale M., Mari M., Rabuffetti M., Benedetto F.R., Visconti G., Bollero E., Roselli M. The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience. Supportive Care in Cancer 2009, 17(5):471-478.
9. Kearney N., McCann L., Norrie J., Taylor L., Gray P., McGee-Lennon M., Sage M., Miller M., Maguire R. Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity. Supportive Care in Cancer 2009, 17(4):437-444.
10. Lyman G.H., Dale D.C., Friedberg J., Crawford J., Fisher R.I. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. Journal of Clinical Oncology 2004, 22(21):4302-4311.
11. Loberiza F.R., Cannon A.J., Weisenburger D.D., Vose J.M., Moehr M.J., Bast M.A., Bierman P.J., Bociek R.G., Armitage J.O. Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study. Journal of Clinical Oncology 2009, 27(32):5376-5382.
12. Marcus A.C., Garrett K.M., Kulchak-Rahm A., Barnes D., Dortch W., Juno S. Telephone counseling in psychosocial oncology: a report from the Cancer Information and Counseling Line. Patient Education and Counseling 2002, 46(4):267-275.
13. Nail L.M., Greene D., Jones L.S., Flannery M. Nursing care by telephone: describing practice in an ambulatory oncology center. Oncology Nursing Forum 1989, 16(3):387-395.
14. Pedrazzoli P., Farris A., Del Prete S., Del Gaizo F., Ferrari D., Bianchessi C., Colucci G., Desogus A., Gamucci T., Pappalardo A., Fornarini G., Pozzi P., Fabi A., Labianca R., Di Costanzo F., Secondino S., Crucitta E., Apolloni F., Del Santo A., Siena S. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. Journal of Clinical Oncology 2006, 26(10):1619-1625.
15. Pettengell R., Schwenkglenks M., Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Annals of Hematology 2008, 87(5):429-430.
16. Pfreundschuh M., Trümper L., Kloess M., Schmits R., Feller A.C., Rübe C., Rudolph C., Reiser M., Hossfeld D.K., Eimermacher H., Hasenclever D., Schmitz N., Loeffler M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104(3):634-641. German High-Grade Non-Hodgkin's Lymphoma Study Group.
17. Pfreundschuh M., Trümper L., Osterborg A., Pettengell R., Trneny M., Imrie K., Ma D., Gill D., Walewski J., Zinzani P.L., Stahel R., Kvaloy S., Shpilberg O., Jaeger U., Hansen M., Lehtinen T., López-Guillermo A., Corrado C., Scheliga A., Milpied N., Mendila M., Rashford M., Kuhnt E., Loeffler M., MabThera International Trial Group CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology 2006, 7(5):357-359.
18. Pfreundschuh M., Schubert J., Ziepert M., Schmits R., Mohren M., Lengfelder E., Reiser M., Nickenig C., Clemens M., Peter N., Bokemeyer C., Eimermacher H., Ho A., Hoffmann M., Mertelsmann R., Trümper L., Balleisen L., Liersch R., Metzner B., Hartmann F., Glass B., Poeschel V., Schmitz N., Ruebe C., Feller A.C., Loeffler M., German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncology 2008, 9(2):105-116.
19. Salar A., Haioun C., Rossi F., Duehrsen U., Pettengell R., Johnsen H.E., Jaeger U., Verhoef G., Schwenkglenks M., Principe F., Bacon P., Bendall K., Lugtenburg P.J. Febrile neutropenia risk assessment and granulocyte-colony stimulating factor support in patients with diffuse large B cell lymphoma receiving R-CHOP regimens. Blood 2009, 114. abstract 107.
20. Schulmeister L. Establishing a cancer patient education system for ambulatory patients. Seminars in Oncology Nursing 1991, 7(2):118-124.
21. Terada Y., Nakamae H., Aimoto R., Kanashima H., Sakamoto E., Aimoto M., Inoue E., Koh H., Nakane T., Takeoka Y., Ohsawa M., Koh K.R., Yamane T., Nakao Y., Ohta K., Mugitani A., Teshima H., Hino M. Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. Journal of Experimental and Clinical Cancer Research 2009, 28:116.
22. Teunissen S.C., Verhagen E.H., Brink M., van der Linden B.A., Voest E.E., de Graeff A. Telephone consultation in palliative care for cancer patients: 5 years of experience in The Netherlands. Supportive Care in Cancer 2007, 15(6):577-582.
23. The International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine 1993, 329(14):987-994.
24. Thieblemont C., Coiffier B. Lymphoma in older patients. Journal of Clinical Oncology 2007, 25(14):1916-1923.
25. Tilly H., Lepage E., Coiffier B., Blanc M., Herbrecht R., Bosly A., Attal M., Fillet G., Guettier C., Molina T.J., Gisselbrecht C., Reyes F., Groupe d'Etude des Lymphomes de l'Adulte Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003, 102(13):4284-4289.
26. Weaver A., Young A.M., Rowntree J., Townsend N., Pearson S., Smith J., Gibson O., Cobern W., Larsen M., Tarassenko L. Application of mobile phone technology for managing chemotherapy-associated side-effects. Annals of Oncology 2007, 18(11):1887-1892.
27. Wilson R., Hubert J. Resurfacing the care in nursing by telephone: lessons from ambulatory oncology. Nursing Outlook 2002, 50(4):160-164.